Evren Saban
Evren Saban has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
- Merve Oztug
TÜBİTAK National Metrology Institute, Kocaeli, Turkiye
3 shared publications Ahmet Baş
2 shared publicationsAhsen Aydın Böyük
2 shared publications- Meltem Asicioglu
TÜBİTAK National Metrology Institute, Kocaeli, Turkiye
2 shared publications - Abdulkeri̇m Eneş
12Department of Computer Engineering, Faculty of Engineering, Harran University, Şanlıurfa, Turkiye
1 shared publication - Abdullah Karadağ
Molecular Oncology Laboratory, Medical Biotechnology Research Group, VPLS, TÜBİTAK Marmara Research Center, Kocaeli, Turkiye
1 shared publication
Latest Publications
- 11 December 2024
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 63 (5) , 1016-1030
Comparative evaluation of peptide vs. protein-based calibration for quantification of cardiac troponin I using ID-LC-MS/MS
Objectives: An analytical protocol based on isotope dilution liquid chromatography-tandem mass spectrometry (ID-LC-MS/MS), which includes a peptide-based calibration strategy, was developed and validated for the determination of cardiac troponin I (cTnI) levels in clinical samples. Additionally, the developed method was compared with a protein-based calibration strategy, using cTnI serving as a model for low-abundant proteins. The aim is to evaluate new approaches for protein quantification in complex matrices, supporting the metrology community in implementing new methods and developing fit-for-purpose SI- traceable peptide or protein primary calibrators. Methods: To establish traceability to SI units, peptide impurity correction amino acid analysis (PICAA) was conducted to determine the absolute content of signature peptides in the primary standards. Immunoaffinity enrichment was used to capture cTnI from human serum, with a comparison between microbeads and nanobeads to improve enrichment efficiency. Parallel reaction monitoring was used to monitor two signature peptides specific to cTnI. Various digestion parameters were optimized to achieve complete digestion. Results: The analytical method demonstrated selectivity and specificity, allowing the quantification of cTnI within 0.9–22.0 μg/L. The intermediate precision RSD was below 28.9 %, and the repeatability RSD was below 5.8 % at all concentration levels, with recovery rates ranging from 87 % to 121 %. The comparison of calibration strategies showed similar LOQ values, but the peptide-based calibration exhibited significant quantitative bias in recovery rates. The data are available via ProteomeXchange (PXD055104). Conclusions: This isotope dilution liquid chromatography-tandem mass spectrometry (ID-LC-MS/MS) method, based on peptide calibration, successfully quantified cTnI in human serum. Comparing this with protein-based calibration highlighted both the strengths and potential limitations of peptide-based strategies.
- 11 December 2024
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 63 (5) , 1016-1030
Comparative evaluation of peptide vs. protein-based calibration for quantification of cardiac troponin I using ID-LC-MS/MS
Objectives: An analytical protocol based on isotope dilution liquid chromatography-tandem mass spectrometry (ID-LC-MS/MS), which includes a peptide-based calibration strategy, was developed and validated for the determination of cardiac troponin I (cTnI) levels in clinical samples. Additionally, the developed method was compared with a protein-based calibration strategy, using cTnI serving as a model for low-abundant proteins. The aim is to evaluate new approaches for protein quantification in complex matrices, supporting the metrology community in implementing new methods and developing fit-for-purpose SI- traceable peptide or protein primary calibrators. Methods: To establish traceability to SI units, peptide impurity correction amino acid analysis (PICAA) was conducted to determine the absolute content of signature peptides in the primary standards. Immunoaffinity enrichment was used to capture cTnI from human serum, with a comparison between microbeads and nanobeads to improve enrichment efficiency. Parallel reaction monitoring was used to monitor two signature peptides specific to cTnI. Various digestion parameters were optimized to achieve complete digestion. Results: The analytical method demonstrated selectivity and specificity, allowing the quantification of cTnI within 0.9–22.0 μg/L. The intermediate precision RSD was below 28.9 %, and the repeatability RSD was below 5.8 % at all concentration levels, with recovery rates ranging from 87 % to 121 %. The comparison of calibration strategies showed similar LOQ values, but the peptide-based calibration exhibited significant quantitative bias in recovery rates. The data are available via ProteomeXchange (PXD055104). Conclusions: This isotope dilution liquid chromatography-tandem mass spectrometry (ID-LC-MS/MS) method, based on peptide calibration, successfully quantified cTnI in human serum. Comparing this with protein-based calibration highlighted both the strengths and potential limitations of peptide-based strategies.
- Open Access
- 26 June 2024
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF BIOLOGY
- Vol. 48 (3) , 203-217
LUNGBANK: A Novel Biorepository Strategy Tailored for Comprehensive Multi-Omics Analysis and P-Medicine Applications in Lung Cancer
Background/aim: LUNGBANK was established as a pioneering biorepository dedicated to lung cancer. Designed for streamlined biospecimens handling, it employs high-volume technologies to secure high-quality samples. Fortified with robust data management, LUNGBANK efficiently integrates diverse datasets. This strategic infrastructure positions LUNGBANK as more than a biospecimens repository; it operates as a sophisticated platform for advanced lung cancer research, amplifying the potential for meaningful discoveries.Materials and methods: LUNGBANK is intricately designed to streamline the collection, transfer, storage, and processing of biospecimens, employing high-volume technologies to ensure the acquisition of high-quality biological specimens. The system is fortified with robust data management protocols, facilitating efficient integration of diverse datasets. This strategic infrastructure ensures that LUNGBANK not only serves as a repository of biospecimens but also operates as a sophisticated platform for advanced lung cancer research.Results: LUNGBANK plays an essential role in furnishing a rich collection of biospecimens essential for unraveling the molecules and mechanisms linked to lung cancer. Rigorous standard operating procedures guided the meticulous collection of biospecimens, subjecting them to stringent quality control measures before inclusion in the study. Moreover, LUNGBANK has proven valuable in the establishment of patient-derived systems. The incorporation of cutting-edge technologies guarantees the acquisition of top-tier data, thereby amplifying the likelihood of substantial breakthroughs in both contemporary translational research and traditional histological evaluations.Conclusion: The establishment of LUNGBANK marks a significant stride towards addressing the pressing need for effective diagnostic and therapeutic systems in lung cancer research. By facilitating the collection and analysis of high-quality biospecimens, LUNGBANK serves as a valuable resource for unraveling the molecular intricacies of lung cancer initiation and progression. This comprehensive system not only supports Project LUNGMARK but also contributes to the broader landscape of personalized medicine, tailoring interventions to the specific needs of lung cancer patients.
- 26 June 2024
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF BIOLOGY
- Vol. 48 (3) , 203-217
Open AccessLUNGBANK: A Novel Biorepository Strategy Tailored for Comprehensive Multi-Omics Analysis and P-Medicine Applications in Lung Cancer
Background/aim: LUNGBANK was established as a pioneering biorepository dedicated to lung cancer. Designed for streamlined biospecimens handling, it employs high-volume technologies to secure high-quality samples. Fortified with robust data management, LUNGBANK efficiently integrates diverse datasets. This strategic infrastructure positions LUNGBANK as more than a biospecimens repository; it operates as a sophisticated platform for advanced lung cancer research, amplifying the potential for meaningful discoveries.Materials and methods: LUNGBANK is intricately designed to streamline the collection, transfer, storage, and processing of biospecimens, employing high-volume technologies to ensure the acquisition of high-quality biological specimens. The system is fortified with robust data management protocols, facilitating efficient integration of diverse datasets. This strategic infrastructure ensures that LUNGBANK not only serves as a repository of biospecimens but also operates as a sophisticated platform for advanced lung cancer research.Results: LUNGBANK plays an essential role in furnishing a rich collection of biospecimens essential for unraveling the molecules and mechanisms linked to lung cancer. Rigorous standard operating procedures guided the meticulous collection of biospecimens, subjecting them to stringent quality control measures before inclusion in the study. Moreover, LUNGBANK has proven valuable in the establishment of patient-derived systems. The incorporation of cutting-edge technologies guarantees the acquisition of top-tier data, thereby amplifying the likelihood of substantial breakthroughs in both contemporary translational research and traditional histological evaluations.Conclusion: The establishment of LUNGBANK marks a significant stride towards addressing the pressing need for effective diagnostic and therapeutic systems in lung cancer research. By facilitating the collection and analysis of high-quality biospecimens, LUNGBANK serves as a valuable resource for unraveling the molecular intricacies of lung cancer initiation and progression. This comprehensive system not only supports Project LUNGMARK but also contributes to the broader landscape of personalized medicine, tailoring interventions to the specific needs of lung cancer patients.
- 12 January 2024
- Published by Springer Nature in Accreditation and Quality Assurance
- Vol. 29 (1) , 19-29
Development of UME CRM 1008: certified reference material for C-reactive protein
- 12 January 2024
- Published by Springer Nature in Accreditation and Quality Assurance
- Vol. 29 (1) , 19-29
Development of UME CRM 1008: certified reference material for C-reactive protein
- 4 June 2022
- Published by Elsevier in International Journal of Thermal Sciences
- Vol. 179, 107595
Inactivation of viruses on surfaces by infrared techniques
- 4 June 2022
- Published by Elsevier in International Journal of Thermal Sciences
- Vol. 179, 107595
Inactivation of viruses on surfaces by infrared techniques